https://scholars.lib.ntu.edu.tw/handle/123456789/628012
標題: | Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation | 作者: | Tsai, Mao-Song HSIN-YUN SUN Chen, Cheng-Pin Lee, Chen-Hsiang Lee, Chun-Yuan Liu, Chun-Eng Tang, Hung-Jen Hung, Tung-Che Li, Chia-Wen Lee, Yuan-Ti Liou, Bo-Huang Yang, Chia-Jui CHIEN-CHING HUNG |
關鍵字: | Genetic barrier; Integrase strand-transfer inhibitor; Low-level viremia; Nucleoside reverse-transcriptase inhibitor; Resistance-associated mutation; Viral rebound | 公開日期: | 一月-2023 | 卷: | 126 | 來源出版物: | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 摘要: | Real-world experience with coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) is sparse as a switch regimen among people living with HIV (PLWH) having achieved viral suppression after previous virologic failures with the emergence of K65N/R. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628012 | ISSN: | 12019712 | DOI: | 10.1016/j.ijid.2022.11.012 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。